SIGHT SCIENCES SGHT 深 沪
等待开盘 10-21 09:30:00 美东时间
4.66
-0.030
-0.64%
华盛通- 最 高5.14
- 今 开4.73
- 成交量 79.82万股
- 最 低 4.49
- 昨 收 4.69
- 总市值 2.44亿
- 52周最高 5.48
- 市盈率 静 --
- 换手率 1.52%
- 52周最低 2.03
- 委 比 8.10%
- 总股本 5236.74万
- 历史最高 42.57
- 量 比 2.10
- 振 幅 13.86%
- 历史最低 1.04
- 每 手 1
- 风险率 1.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sight Sciences Secures Medicare Pricing For TearCare Eyelid Treatment, Expanding Coverage Across Novitas And First Coast Jurisdictions
Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve
10-17 19:03
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
Sight Sciences, Inc. announced that two Medicare Administrative Contractors, Novitas Solutions and First Coast Service Options, have established pricing for CPT code 0563T, which covers the TearCare procedure. Effective January 1, 2025, the pricing applies to 10.4 million Medicare beneficiaries in jurisdictions administered by these MACs. The procedure involves heat therapy to address meibomian gland dysfunction causing dry eye disease. Sight Sci...
10-17 11:00
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $4
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and lowers the price target from $4.5 to $4.
10-08 01:48
Sight Sciences Amends Loan Agreement with Hercules
An update from Sight Sciences ( ($SGHT) ) is now available. On September 30, 20...
10-01 04:28
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
The study, published in The European Journal of Ophthalmology, concludes that the OMNI Surgical System is a beneficial treatment option for patients with primary open-angle glaucoma due to its favorable long-term safety and efficacy profiles. The meta-analysis of 29 publications and 2,379 eyes demonstrated consistent, significant reductions in intraocular pressure (IOP) and medication use, with long-term durability. Adverse events were mild and t...
09-17 11:00
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments
Sight Sciences announced that UnitedHealthcare has updated its policy to cover four implant-free MIGS procedures, including those using OMNI Surgical System technology, for treating open-angle glaucoma and cataract in adults. The coverage, effective October 1, 2025, applies to UHC's commercial and individual exchange plans, covering approximately 30 million people. OMNI technology reduces intraocular pressure and can be performed alongside catara...
09-09 11:05
Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO
Sight Sciences’ TearCare System has been included in the TFOS DEWS III report, a key evidence-based standard for dry eye disease (DED) management. The report highlights multiple studies demonstrating TearCare’s clinical efficacy, including its superiority in improving Tear Breakup Time and gland function compared to Restasis® in the SAHARA trial, and significant symptom alleviation in a single treatment shown in the OLYMPIA RCT. TearCare’s recogn...
09-02 20:05
Needham Reiterates Hold on Sight Sciencesto Hold
Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) from Hold to Hold.
08-29 00:44
Sight Sciences Announces Workforce Reduction Plan
The latest announcement is out from Sight Sciences ( ($SGHT) ). On August 27, 2...
08-28 04:35
